Valneva SE (VALN) Revenue (2021 - 2026)
Valneva SE's (VALN) quarterly Revenue came in at $35.7 million in Q1 2026, down 30.11% year-on-year from $51.1 million in Q1 2025, and down 20.28% quarter-over-quarter from $44.8 million in Q4 2025.
Valneva SE (VALN) Revenue (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Revenue across 6 years of filings, most recently posting $35.7 million for Q1 2026.
- Revenue for Q1 2026 came in at $35.7 million, down 30.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $161.7 million (down 16.14% YoY), and the FY2025 annual result was $183.8 million, up 5.33% from the prior year.
- Revenue came in at $35.7 million for Q1 2026 at Valneva SE, down from $44.8 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $54.3 million in Q4 2024 to a low of $18.1 million in Q1 2022.
- The 5-year median for Revenue is $40.9 million (2023), against an average of $39.7 million.
- Across the five-year window, Revenue surged 156.28% in 2022 and plunged 31.68% in 2025, its largest moves.
- Valneva SE's Revenue stood at $41.2 million in 2022, then climbed by 24.28% to $51.2 million in 2023, then gained by 6.03% to $54.3 million in 2024, then fell by 17.44% to $44.8 million in 2025, then decreased by 20.28% to $35.7 million in 2026.
- The last three Revenue figures came in at $35.7 million (Q1 2026), $44.8 million (Q4 2025), and $33.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 35.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.73 Mn |
| Dec 31, 2025 | 44.82 Mn |
| Sep 30, 2025 | 33.18 Mn |
| Jun 30, 2025 | 48.02 Mn |
| Mar 31, 2025 | 51.12 Mn |
| Dec 31, 2024 | 54.28 Mn |
| Sep 30, 2024 | 48.56 Mn |
| Jun 30, 2024 | 38.91 Mn |
| Mar 31, 2024 | 34.93 Mn |
| Dec 31, 2023 | 51.20 Mn |
| Sep 30, 2023 | 39.70 Mn |
| Jun 30, 2023 | 40.91 Mn |
| Mar 31, 2023 | 34.45 Mn |
| Dec 31, 2022 | 41.19 Mn |
| Sep 30, 2022 | 41.43 Mn |
| Jun 30, 2022 | 18.32 Mn |
| Mar 31, 2022 | 18.14 Mn |
| Dec 31, 2021 | 20.04 Mn |
| Sep 30, 2021 | 16.16 Mn |
| Jun 30, 2021 | 18.83 Mn |